251 related articles for article (PubMed ID: 12030116)
1. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
Kennel SJ; Chappell LL; Dadachova K; Brechbiel MW; Lankford TK; Davis IA; Stabin M; Mirzadeh S
Cancer Biother Radiopharm; 2000 Jun; 15(3):235-44. PubMed ID: 10941530
[TBL] [Abstract][Full Text] [Related]
3. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
[TBL] [Abstract][Full Text] [Related]
4. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.
Woodward J; Kennel SJ; Stuckey A; Osborne D; Wall J; Rondinone AJ; Standaert RF; Mirzadeh S
Bioconjug Chem; 2011 Apr; 22(4):766-76. PubMed ID: 21434681
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
7. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
8. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
[TBL] [Abstract][Full Text] [Related]
9. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
12. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.
Xiao J; Horst S; Hinkle G; Cao X; Kocak E; Fang J; Young D; Khazaeli M; Agnese D; Sun D; Martin E
Cancer Biother Radiopharm; 2005 Feb; 20(1):16-26. PubMed ID: 15778575
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
15. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
17. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
18. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
